Smumary The efficacy of radioimmunotherapy of tumours with radiolabelled monoclonal antibodies (MAbs) depends on the amount of antibody taken up by the tumour and on its intratumoral distribution. In the case of MAbs directed against intracellular antigens, increasing the permeability of the cytoplasmic membrane may augment the bioavailability of the antigen for the antibody. This raises the question whether the induction of tumour necrosis by chemotherapy can enhance the tumour uptake of radiolabelled monoclonal antibodies. In this work, the effect of doxorubicin on the biodistribution of Po66, an MAb directed against an intracellular antigen, was studied in nude mice grafted with the human non-small-cell lung carcinoma cell line SK-MES-1.
Monoclonal antibody-targeted radiotherapy relies on differential radioisotope uptake in tumour and tissues. This first requires that the amount of circulating radiolabelled monoclonal antibody (MAb) should be as low as possible to minimise non-specific irradiation of normal tissues. Second, the tumour uptake of MAb should be as elevated and longlasting as possible to deliver sufficient radiation to the tumour.
Several techniques have been devised to overcome the non-specific irradiation due to persistence of the radiolabelled MAb in the circulation. Among these are the use of F(ab')2 fragments, which are cleared rapidly from blood (Buchsbaum et al., 1990; Sharkey et al., 1990) , and the injection of a second antibody provoking the formation of immune complexes, which are rapidly eliminated from blood (Blumenthal et al., 1988) . Unbound antibody can also be removed from the circulation by means of immunoadsorption (Lear et al., 1991) . Non-speific irradiation should be minimised by the use of two-step MAb-targeting techniques, combining first the administration of bifunctional (Le Doussal et al., 1989; Bosslet et al., 1991) or pretargeted MAbs (streptavidinylated or enzyme conjugated) (Kalafonos et al., 1990; Hawkins et al., 1993) , and second the injection of hapten-, biotin-or substrate-bound radionucides, which are rapidly cleared from blood.
The amount of MAb taken up by tumours depends on several biological parameters, such as molecular size, the specificity and affinity of the MAb, the amount and location of the anitgen, as well as tumoral size, vasculature and interstitial pressure (Jain, 1990) and the host response to foreign immunoglobulin (Reynolds et al., 1989) . As a general rule, the proportion of MAb taken up by the tumour is low (0.001-0.1% of the injected dose in man), and distribution of MAbs within the tumours is heterogeneous. Accordingly, several techniques have been proposed to enhance the tumour uptake of MAbs. An increase in MAb affinity can enhance tumour uptake of MAbs (Schlom et al., 1992) . The use of F(ab')2 or Fab fragments improves penetration of tumours (Endo et al., 1988; Buchsbaum et al., 1990; Sharkey et al., 1990) . The amount of MAb injected can be increased until antigenic sites are saturated (Goodman et al., 1993) . The use of several MAbs of different specificity, or recognising different epitopes of the same tumour-associated antigen (Buchegger et al., 1989) , increases antibody uptake. It has also been proposed to increase tumour antigen expression with interferon (Rosenblum et al., 1988) , or to modify tumoral vasculature with interleukin 2 (Nakamura et al., 1994) or interleukin 2 immunoconjugate (LeBerthon et al., 1991) in order to improve the accessibility to tumour antigens.
With MAbs directed against intracellular antigens, the ability of the antibody to reach its target depends on tumour cell membrane permeability. The latter is increased at various stages of the cell degeneration process which occurs spontaneously in tumours, even at an early stage of their growth (Cooper et al., 1975) . Tumour necrosis may be increased by chemotherapy. This results in enhanced accessibility of intracytoplasmic tumour antigens to MAbs. In this study, we used a tumour-bearing mouse model, to described the biodistribution of Po66, an MAb directed against a still unknown cytoplasmic antigen present in non-small-cell lung carcinoma. We show that administration of doxorubicin enhances the uptake of '"-I-radiolabelled Po66 by tumours and improves the homogeneity of the distribution of the MAb throughout the tumours.
Materials and methods
Production and radioiodination of monoclonal antibodies MAb Po66, a mouse IgGI, was obtained as described previously (Dazord et al., 1987 Figure la . show that the peak accumulation occurred between days 3 and 5. with 6.4 ± 1.3 and 7.1 ± 0.8% ID g-' of tumour respectively (mean ± s.d.). The radioactivity uptake remained elevated for at least 14 days (6.1 ± 0.9% ID g-') in the tumour while decreasing in the blood and organs (Table I ). Figure lb shows that the tumour uptake of the unrelated '25I-labelled Py MAb was 2-3 times lower than that of ["UI]Po66 after 24 h. while it did not differ in normal tissues. These results are in agreement with previous reports using human lung carcinoma xenografts (Desrues et al., 1989) .
Immunoperoxidase staining of tissue sections of SK-MES-I tumours showed that the antigen recognised by Po66 was present in almost all tumour cells and that the dye was distributed homogeneously throughout the tumour, i.e. in both apparently viable cells and necrotic cells (figure not shown). To determine the microscopic location of antibodies +i +1 +i +, +i, +t +i +l +1 +i Figure 4 , doxorubicin n twice i.v. (I week interval) transiently decreased the growth curve of tumours in the time course of the experiments. This difference was not statistically siifnt, and 14 days after the last injection, the slope of the curve of tumour growth in the doxorubicin-treated group was similar to the slope of the control tumours. The extent of necrosis was determined histologicaily. In non-treated mice an average of 1-2 areas of necrosis were present in the central part of tumours (15-30% of the section area), although in doxorubicin-treated mice 3-4 areas of more extended necrosis were observed (40-70% of the section area). Figures 2a and 5a are representative of the appearance and the extent of necrosis in control and doxorubidn-treated mice. In the D -7/DO schedule, however, the necrosis was less extensive on day 14 than on day 5. Figure 6 shows the % ID g-' of tumour in control and Figure   5a clearly shows, at low magnification, that in contrast to controls (Figure 2a) , treatment with doxorubicin induced numerous necrotic areas that bound silver grains. At higher magnification (Figure 5b ), in areas adjacent to necrosis, many spots of silver grain were observed, and were probably related to the binding of ['"I] Po66 to degenerating cells.
Necrosis was, therefore. accompanied by a more homogeneous distribution of radiolabelled Po66 in tumours.
As reported above (Figure 3 ), the uptake of radiolabelled Po66 by the tumour reached a plateau for an injection of above 100 ;g MAb per mouse. This plateau was examined in doxorubicin-treated mice. The administration of doxorubicin significantly increased the tumour uptake of 200 tg of ['VI]Po66 on day 5, particularly when doxorubicin was administered before Po66 (D -7DO; Figure 7) . On day 14, according to previous observations, the tumour uptake was higher when doxorubicin was administered with the DO, D + 7 schedule. This phenomenon is probably due to the fact that more antigenic sites were accessible after doxorubicin treatment.
Po66, like other MAbs directed against intracellular antigens (Epstein et al., 1988) . binds predominantly to necrotic areas of tumours. This is probably because of the ability of the MAb to cross damaged cytoplasmic membranes. The most important problem raised by such antibodies is that they cannot reach their target in viable cells. Also, the access of the MAb to the necrotic zones may be difficult, owing to unfavourable physicochemical conditions in the central parts of bulky tumours with poor vasculature. and altered pH and hydrostatic pressure (Jain, 1990) . Another limitation for these MAbs is that the amount of accessible antigen depends on the degree of necrosis, which is variable and unpredictable.
MAbs directed against internal antigens may have, however, several advantages. First, the intracytoplasmic localisation offers a double binding specificity:antigen-antibody interaction, and access to antigen only in damaged tumour cells, a specific pattern of tumours, even at an early stage of development (Cooper et al., 1975 vitro models which showed good diffusion of MAbs throughout thee-dimensional culture systems (Carisson et al., 1989; Dazord et al., 1993) . Third, another important advantage of anti-internal antigen antibodies is their prolonged retention time in the tumours (Welt et al., 1987) . Po66 was still detected at high levels in the tumour up to 14 days post injection. In man, Po66 was also found to persist for a long time (Bourguet et al., 1990 ). This situation is very favourable for the two-step therapies described in the introduction. Fourth, as shown here with Po66, it was possible to enhance tumour uptake of the MAb by means of chemotherapy. This correlated with the induction of necrosis as observed histologically. However, it remains possible that doxorubicin treatment increases tumour blood flow by dilating vessels near the necrotic areas, thus leading to increased antibody delivery, as has been shown with radiation and hyperthermia (Stickney et al., 1987) . In the D -7/DO protocol, the uptake of Po66 was more elevated than in controls on days 3 and 5, but identical on day 14. This is probably due to a repopulation of the tumour by new dividing cells, 2 and 3 weeks after treatment with doxorubicin, as would be expected from the growth curve. When doxorubicin was on days 0 and 7, high uptake on days 9 and 14 was observed, suggesting that this protocol of doxorubicin administration maintained necrosis within tumours and probably allowed more persistent access to the antigen by Po666 rather than doxorubicin-induced trapping of the MAb in new necrotic areas. This suggests that for an optimal effect, chemotherapy and radiolabelled MAb should be separated by a relatively short interval.
In terms of radiolabeled MAbs as potential tools in cancer treatment, the present investigation in a mouse model leads to some speculations. As shown in Figure 2a , it is possible that a medium-range radioisotope like iodine-131 would not reach and destroy distant viable cells at the edge of the tumour. However, sequential injection of radiolabelled antibody could produce an ever expanding population of new target cells in the tumour as a result of the centrifual lling of adjacent viable tumour cells, as has been shown previously with an antibody directed against an intracellular antigen (Chen et al., 1989) . However, the combination of chemotherapy with radiolabelled MAbs directed against a cytoplasmic antigen might produce a synergistic effect. Improved diffusion of the MAb throughout the tumour may result in the irradiation of the last drug-resistant cells, by a cross-fire effect from all necrotic areas induced by chemotherapy. The treatment would be particularly beneficial for small scattered metastases. The question arises whether the combination of both drugs would also enhance bone marrow toxicity. It is important to note that the antigen recognised by Po66 is not present in haematopoietic cells (Dazord et al., 1987) , and that the lysis of these cells by the associated chemothereapy would not sensitise them to irradiation as intensely as tumour cells. In contrast, MAbs directed against ubiquitous intracellular antigens like histones (Epstein et al., 1988) could have such an effect.
On the other hand, it is likely that the non-specific irradiation due to cirulating radiolabelled MAb, combined with chemotherapy, would prove toxic for haematopoietic bone stem cells. Although bone marrow support has been proposed in immunoradiotherapy protocols (Press et al., 1993) , it would be preferable to minimise this non-specific toxicity. This could be done by using Po66 as the first part of a two-step treatment. The principles of this technique were outlined in the introduction. Po66 is a particularly good candidate for such use. Its retention in tumours is prolonged, even if the MAb fraction remaining in the circulation is artificially reduced (Desrues et al., 1995) .
Cancer treatment with radiolabelled MAbs raises important problems of dosimetry. In the mathematical formulae for the alculation of the radiation dose, it is usually assumed that the irradiation source is uniformly distributed in the tissue, which is obviously not the case for MAbs (Zalcberg et al., 1981; Badger et al., 1986) . Microscopic dosimetry seems more appropriate for MAbs (Humm et al., 1990 ), but is difficult to compute. Consequently, to appreciate the additive effect of immunoradiotherapy and chemotherapy, animal models such as that described here seem more suitable than theoretical and in wvtro investigations. Treatment of lung cancer in the mouse model described in the present work by combining chemotherapy and tumoricidal doses of ['3'I] Po66 is curently under investigation in our laboratory.
